← Back to Search
Monoclonal Antibodies
Pembrolizumab for Lung Cancer
Ottawa, Canada
Phase 2 & 3
Recruiting
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must be ≥ 18 years of age.
Patients must have a PD-L1 test result from a certified laboratory indicating PD-L1 expression Tumour Proportion Score (TPS) ≥ 1%.
Must not have
Concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether blood tests can show how well pembrolizumab is working against cancer.
See full description
Who is the study for?
Adults with metastatic Non-Small Cell Lung Cancer (NSCLC) who haven't had systemic chemotherapy or immunotherapy for advanced cancer. They must have a PD-L1 expression score of at least 1%, be in good physical condition, and agree to use effective contraception. Not eligible if they've had certain other cancers, are pregnant, have untreated brain metastases requiring steroids, or conditions that pembrolizumab could worsen.Check my eligibility
What is being tested?
The trial is testing whether blood tests can effectively monitor the response to pembrolizumab treatment in NSCLC patients. Pembrolizumab is an immunotherapy drug designed to help the body's immune system fight cancer cells.See study design
What are the potential side effects?
Pembrolizumab may cause immune-related side effects such as inflammation of organs like lungs or intestines, skin reactions, hormonal gland problems (like thyroid), fatigue, infusion reactions and may increase infection risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
show original
Select...
My cancer shows a PD-L1 level of 1% or higher.
show original
Select...
I am fully active or can carry out light work.
show original
Select...
My lung cancer is confirmed and has spread, but I can't have surgery or targeted radiation.
show original
Select...
My cancer can be measured by scans according to RECIST 1.1.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not currently receiving any other cancer treatments.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Stage 1: Concordance rate between molecular response and radiologic response
Side effects data
From 2024 Phase 3 trial • 804 Patients • NCT0304099964%
Radiation skin injury
63%
Stomatitis
58%
Anaemia
56%
Nausea
48%
Dry mouth
45%
Constipation
45%
Weight decreased
44%
Dysphagia
42%
Neutrophil count decreased
33%
Vomiting
33%
Dysgeusia
32%
Fatigue
31%
White blood cell count decreased
28%
Hypomagnesaemia
26%
Decreased appetite
25%
Hypothyroidism
25%
Hypokalaemia
24%
Lymphocyte count decreased
24%
Platelet count decreased
23%
Blood creatinine increased
23%
Oropharyngeal pain
22%
Diarrhoea
22%
Odynophagia
20%
Hypoacusis
20%
Alanine aminotransferase increased
20%
Hyponatraemia
19%
Tinnitus
19%
Asthenia
19%
Oral candidiasis
16%
Pyrexia
16%
Cough
15%
Aspartate aminotransferase increased
15%
Rash
14%
Insomnia
13%
Acute kidney injury
13%
Pharyngeal inflammation
13%
Pruritus
12%
Gamma-glutamyltransferase increased
12%
Dysphonia
11%
Pneumonia
11%
Dehydration
10%
Hyperthyroidism
10%
Hypoalbuminaemia
10%
Hypocalcaemia
10%
Headache
10%
Productive cough
9%
Neck pain
9%
Peripheral sensory neuropathy
8%
Gastrooesophageal reflux disease
8%
Hyperglycaemia
8%
Hyperuricaemia
8%
Hypophosphataemia
8%
Dizziness
8%
Hiccups
7%
Ear pain
7%
Oral pain
7%
Localised oedema
7%
Urinary tract infection
7%
Hyperkalaemia
7%
Erythema
6%
Abdominal pain upper
6%
Dyspepsia
6%
Saliva altered
6%
Arthralgia
6%
Anxiety
6%
Febrile neutropenia
5%
Oedema peripheral
5%
Back pain
5%
Dyspnoea
5%
Hypertension
4%
Nasopharyngitis
4%
Alopecia
4%
Dry skin
3%
Pneumonia aspiration
3%
Sepsis
3%
Pneumonitis
3%
Trismus
3%
Laryngeal oedema
2%
Cellulitis
2%
Malnutrition
2%
Pharyngeal haemorrhage
1%
Colitis
1%
Mouth haemorrhage
1%
Oesophagitis
1%
Death
1%
General physical health deterioration
1%
Hypersensitivity
1%
Device related infection
1%
Hepatitis
1%
Immune-mediated hepatitis
1%
Abscess neck
1%
Bronchitis
1%
Clostridium difficile colitis
1%
Hypercalcaemia
1%
Septic shock
1%
Stoma site infection
1%
Systemic infection
1%
Vascular device infection
1%
Wound infection
1%
Hypophagia
1%
Tumour haemorrhage
1%
Syncope
1%
Cerebrovascular accident
1%
Acute respiratory failure
1%
Aspiration
1%
Pulmonary embolism
1%
Respiratory failure
1%
Acute myocardial infarction
1%
Cardiac arrest
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pembrolizumab + CRT Followed by Pembrolizumab
Placebo + CRT Followed by Placebo
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Pembrolizumab + standard platinum-based chemotherapyExperimental Treatment1 Intervention
Per current Product Monograph/U.S. Drug Label and/or local guidelines.
Group II: Pembrolizumab aloneActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2630
Find a Location
Closest Location:Juravinski Cancer Centre at Hamilton Health Sciences· Hamilton, Canada· 280 miles
Who is running the clinical trial?
Personal Genome DiagnosticsIndustry Sponsor
3 Previous Clinical Trials
1,474 Total Patients Enrolled
Mark Foundation for Cancer ResearchUNKNOWN
Cancer Research Institute, New York CityOTHER
21 Previous Clinical Trials
1,078 Total Patients Enrolled
Canadian Cancer Trials GroupLead Sponsor
133 Previous Clinical Trials
70,082 Total Patients Enrolled
Personal Genome Diagnostics (PGDx)UNKNOWN
1 Previous Clinical Trials
1,320 Total Patients Enrolled
Cheryl HoStudy ChairBCCA - Vancouver Cancer Centre
Sara MooreStudy ChairOttawa Hospital Research Institute
Valsamo AnagnostouStudy ChairJohns Hopkins University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.My recent blood and organ function tests are within normal ranges.I can start treatment within 2 days of joining the trial.I haven't had chemo or immunotherapy for advanced lung cancer but may have had it for earlier stages.I cannot take pembrolizumab due to an active infection, autoimmune disease, need for immunosuppressants, severe immune reactions, or allergy to it.My cancer shows a PD-L1 level of 1% or higher.I am not currently receiving any other cancer treatments.I've had recent scans of my chest, abdomen, pelvis, and brain to document my cancer.My lung cancer does not have EGFR or ALK mutations, or I have squamous cell lung cancer.I had major surgery over 28 days ago and my wound has healed.I had cancer before, but it won't affect this trial's treatment.I have recovered from side effects of my previous cancer treatments.I agree to use birth control if I or my partner can become pregnant.I have brain metastases but am stable on low-dose steroids or have no symptoms.I am fully active or can carry out light work.I can be treated with pembrolizumab and understand it might not be covered everywhere.My lung cancer is confirmed and has spread, but I can't have surgery or targeted radiation.My cancer can be measured by scans according to RECIST 1.1.
Research Study Groups:
This trial has the following groups:- Group 1: Pembrolizumab alone
- Group 2: Pembrolizumab + standard platinum-based chemotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.